Literature DB >> 1326822

Involvement of FOS and JUN in the activation of visna virus gene expression in macrophages through an AP-1 site in the viral LTR.

D S Shih1, L M Carruth, M Anderson, J E Clements.   

Abstract

Gene expression of visna virus is highly restricted in monocytes, but is induced when monocytes differentiate into macrophages. A previous study on differential regulation of visna virus gene expression revealed that a specific AP-1 site in the long terminal repeat of the viral DNA is required for phorbol-ester-induced gene expression in macrophages (Gabuzda, Hess, Small, and Clements, Mol. Cell. Biol., 9, 2728-2733). In the present investigation, we examined the association of two DNA binding proteins, the proto-oncogene proteins FOS and JUN, with this AP-1 site in the visna virus LTR. We demonstrated that the concentrations of these two proteins and their mRNAs increased in U937 cells after phorbol ester induction. Furthermore, the binding of cellular proteins from the U937 nuclear extracts to this AP-1 site was significantly decreased in the presence of antibodies to JUN and FOS. In vitro-translated JUN protein also binds to this AP-1 sequence, and this binding is enhanced by the FOS protein. These results indicate that JUN and FOS are directly involved in the differential regulation of visna virus gene expression.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1326822     DOI: 10.1016/0042-6822(92)91194-y

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  12 in total

1.  Visna virus-induced activation of MAPK is required for virus replication and correlates with virus-induced neuropathology.

Authors:  Sheila A Barber; Linda Bruett; Brian R Douglass; David S Herbst; M Christine Zink; Janice E Clements
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

2.  The leucine domain of the visna virus Tat protein mediates targeting to an AP-1 site in the viral long terminal repeat.

Authors:  L M Carruth; B A Morse; J E Clements
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

3.  STAT1 pathway is involved in activation of caprine arthritis-encephalitis virus long terminal repeat in monocytes.

Authors:  T Sepp; S E Tong-Starksen
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

4.  Roles of the auxiliary genes and AP-1 binding site in the long terminal repeat of feline immunodeficiency virus in the early stage of infection in cats.

Authors:  Y Inoshima; M Kohmoto; Y Ikeda; H Yamada; Y Kawaguchi; K Tomonaga; T Miyazawa; C Kai; T Umemura; T Mikami
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

Review 5.  Molecular biology and pathogenesis of animal lentivirus infections.

Authors:  J E Clements; M C Zink
Journal:  Clin Microbiol Rev       Date:  1996-01       Impact factor: 26.132

6.  Targeting of the visna virus tat protein to AP-1 sites: interactions with the bZIP domains of fos and jun in vitro and in vivo.

Authors:  B A Morse; L M Carruth; J E Clements
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

7.  Visna virus Tat protein: a potent transcription factor with both activator and suppressor domains.

Authors:  L M Carruth; J M Hardwick; B A Morse; J E Clements
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

8.  Activation of caprine arthritis-encephalitis virus long terminal repeat by gamma interferon.

Authors:  S E Tong-Starksen; T Sepp; A S Pagtakhan
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

9.  Rabies virus replication in primary murine bone marrow macrophages and in human and murine macrophage-like cell lines: implications for viral persistence.

Authors:  N B Ray; L C Ewalt; D L Lodmell
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

Review 10.  Expanding possibilities for intervention against small ruminant lentiviruses through genetic marker-assisted selective breeding.

Authors:  Stephen N White; Donald P Knowles
Journal:  Viruses       Date:  2013-06-14       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.